Literature DB >> 26181937

Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence.

Seunggu J Han1, Dario J Englot, Harjus Birk, Annette M Molinaro, Susan M Chang, Jennifer L Clarke, Michael D Prados, Jennie W Taylor, Mitchel S Berger, Nicholas A Butowski.   

Abstract

ABBREVIATIONS: EORTC/NCIC, European Organisation for Research and Treatment of Cancer/National Cancer Institute of CanadaGBM, glioblastomaOS, overall survivalPFS, progression-free survivalSEER, Surveillance, Epidemiology, and End ResultsTMZ, temozolomide.

Entities:  

Mesh：

Year:  2015        PMID： 26181937      PMCID： PMC5260825          DOI： 10.1227/NEU.0000000000000801

Source DB:  PubMed          Journal:  Neurosurgery        ISSN： 0148-396X            Impact factor:   4.654


  27 in total

1.  Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.

Authors:  Georges Noel; Aymeri Huchet; Loic Feuvret; Jean Philippe Maire; Pierre Verrelle; Emilie Le Rhun; Maud Aumont; François Thillays; Marie Pierre Sunyach; Chantal Henzen; Fernand Missohou; Renaud de Crevoisier; Pierre Yves Bondiau; Philippe Collin; Xavier Durando; Gilles Truc; Christine Kerr; Valérie Bernier; Jean-Baptiste Clavier; David Atlani; Anne D'Hombres; Sandrine Vinchon-Petit; Jean Léon Lagrange; Luc Taillandier
Journal:  J Neurooncol       Date:  2012-06-02       Impact factor: 4.130

2.  A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.

Authors:  Jennifer L Clarke; Annette M Molinaro; Joanna J Phillips; Nicholas A Butowski; Susan M Chang; Arie Perry; Joseph F Costello; Ashley A DeSilva; Jane E Rabbitt; Michael D Prados
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

3.  partDSA: deletion/substitution/addition algorithm for partitioning the covariate space in prediction.

Authors:  Annette M Molinaro; Karen Lostritto; Mark van der Laan
Journal:  Bioinformatics       Date:  2010-04-07       Impact factor: 6.937

4.  The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma.

Authors:  L Kleinberg; S A Grossman; S Piantadosi; M Zeltzman; M Wharam
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-06-01       Impact factor: 7.038

5.  Irradiation after surgically induced brain injury in the rat: timing in relation to severity of radiation damage.

Authors:  Selcuk Peker; Ufuk Abacioglu; Ibrahim Sun; Meral Yuksel; M Necmettin Pamir
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

6.  Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.

Authors:  Nicholas Butowski; Susan M Chang; Kathleen R Lamborn; Mei Yin Polley; R Parvataneni; Maria Hristova-Kazmierski; Luna Musib; Steven J Nicol; Donald E Thornton; Michael D Prados
Journal:  Neuro Oncol       Date:  2010-02-15       Impact factor: 12.300

7.  A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects.

Authors:  Lara Barazzuol; Neil G Burnet; Raj Jena; Bleddyn Jones; Sarah J Jefferies; Norman F Kirkby
Journal:  J Theor Biol       Date:  2009-10-17       Impact factor: 2.691

8.  Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme.

Authors:  A Taghian; J Ramsay; J Allalunis-Turner; W Budach; D Gioioso; F Pardo; P Okunieff; N Bleehen; R Urtasun; H Suit
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-01-15       Impact factor: 7.038

9.  Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

Authors:  Olivier L Chinot; Maryline Barrié; Stephane Fuentes; Nathalie Eudes; Sophie Lancelot; Philippe Metellus; Xavier Muracciole; Diane Braguer; L'Houcine Ouafik; Pierre-Marie Martin; Henry Dufour; Dominique Figarella-Branger
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

10.  Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment.

Authors:  N G Burnet; R Jena; S J Jefferies; S P Stenning; N F Kirkby
Journal:  Clin Oncol (R Coll Radiol)       Date:  2006-03       Impact factor: 4.126
View more
  10 in total

1.  Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes.

Authors:  Javier E Villanueva-Meyer; Seunggu J Han; Soonmee Cha; Nicholas A Butowski
Journal:  J Neurooncol       Date:  2017-05-31       Impact factor: 4.130

Review 2.  Newly Diagnosed Glioblastoma: A Review on Clinical Management.

Authors:  Rimas V Lukas; Derek A Wainwright; Erik Ladomersky; Sean Sachdev; Adam M Sonabend; Roger Stupp
Journal:  Oncology (Williston Park)       Date:  2019-03-13       Impact factor: 2.990

3.  The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Francesco Marampon; Alessandro Colapietro; Simona Delle Monache; Roberta Sferra; Flora Vitale; Peter J Richardson; Lee Patient; Stephen Burbidge; Claudio Festuccia
Journal:  J Hematol Oncol       Date:  2017-01-05       Impact factor: 17.388

4.  Branched multipeptide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99.

Authors:  Young-Hee Kim; Thi-Anh-Thuy Tran; Hyun-Ju Lee; Sook-In Jung; Je-Jung Lee; Wool-Youl Jang; Kyung-Sub Moon; In-Young Kim; Shin Jung; Tae-Young Jung
Journal:  Oncotarget       Date:  2016-08-02

Review 5.  Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.

Authors:  Franciele Aline Bruinsmann; Gustavo Richter Vaz; Aline de Cristo Soares Alves; Tanira Aguirre; Adriana Raffin Pohlmann; Silvia Stanisçuaski Guterres; Fabio Sonvico
Journal:  Molecules       Date:  2019-11-26       Impact factor: 4.411

6.  Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy.

Authors:  Xiaoman Mao; Pilar Calero-Pérez; David Montpeyó; Jordi Bruna; Victor J Yuste; Ana Paula Candiota; Julia Lorenzo; Fernando Novio; Daniel Ruiz-Molina
Journal:  Nanomaterials (Basel)       Date:  2022-04-05       Impact factor: 5.076

Review 7.  Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?

Authors:  Daniel Ruiz-Molina; Xiaoman Mao; Paula Alfonso-Triguero; Julia Lorenzo; Jordi Bruna; Victor J Yuste; Ana Paula Candiota; Fernando Novio
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

Review 8.  The Glioblastoma Microenvironment: Morphology, Metabolism, and Molecular Signature of Glial Dynamics to Discover Metabolic Rewiring Sequence.

Authors:  Assunta Virtuoso; Roberto Giovannoni; Ciro De Luca; Francesca Gargano; Michele Cerasuolo; Nicola Maggio; Marialuisa Lavitrano; Michele Papa
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

9.  Antitumor Effects of 5-Aminolevulinic Acid on Human Malignant Glioblastoma Cells.

Authors:  Mohammad Jalili-Nik; Farzaneh Abbasinezhad-Moud; Sajad Sahab-Negah; Abolfazl Maghrouni; Mohammad Etezad Razavi; Maryam Khaleghi Ghadiri; Walter Stummer; Ali Gorji
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

10.  Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model.

Authors:  Kelly J McKelvey; Amanda L Hudson; Ramyashree Prasanna Kumar; James S Wilmott; Grace H Attrill; Georgina V Long; Richard A Scolyer; Stephen J Clarke; Helen R Wheeler; Connie I Diakos; Viive M Howell
Journal:  PLoS One       Date:  2020-04-02       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.